PD-1/PD-L1
PD-1/PD-L1 inhibitors are immune checkpoint inhibitors that block the interaction between the programmed cell death protein 1 (PD-1) on T cells and its ligand PD-L1 on cancer cells. This interaction normally suppresses the immune response and allows cancer cells to evade immune detection. By inhibiting PD-1/PD-L1, these inhibitors enhance the immune system's ability to recognize and destroy cancer cells, inducing apoptosis and tumor regression. PD-1/PD-L1 inhibitors are critical in immunotherapy research and cancer treatment. At CymitQuimica, we offer a range of high-quality PD-1/PD-L1 inhibitors to support your research in immuno-oncology, apoptosis, and cancer therapy.
Found 125 products of "PD-1/PD-L1"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
N-deacetylated BMS-202
CAS:N-deacetylated BMS-202 is an inhibitor of PD-1/PD-L1 interaction with potential anticancer activity for cancer research.Formula:C23H27N3O2Purity:98.13% - 98.13%Color and Shape:SolidMolecular weight:377.48BMS-1166
CAS:BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor.Formula:C36H33ClN2O7Purity:99.22%Color and Shape:SolidMolecular weight:641.11Ref: TM-T5697
1mg71.00€5mg146.00€10mg213.00€25mg406.00€50mg602.00€100mg893.00€200mg1,198.00€1mL*10mM (DMSO)197.00€Pembrolizumab
CAS:Pembrolizumab (MK-3475) is a humanized monoclonal antibody.Cost-effective and quality-assured.Purity:95% - 99.70%Color and Shape:LiquidMolecular weight:149 kDaNivolumab
CAS:Nivolumab is a monoclonal antibody, a humanized IgG4 antibody to PD-1. Nivolumab has antitumor activity. Cost-effective and quality-assured.Purity:98% - 98%Color and Shape:LiquidMolecular weight:143.62 kDaAvelumab
CAS:Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody. Avelumab shows potential antibody-dependent cell-mediated cytotoxicity.Purity:95% - 97.17% (SDS-PAGE)Color and Shape:LiquidMolecular weight:143.8 kDaBMS-8
CAS:BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction (IC50: 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers.Formula:C27H28BrNO3Purity:98.88%Color and Shape:SolidMolecular weight:494.42Ref: TM-T26859
1mg37.00€5mg79.00€10mg124.00€25mg222.00€50mg340.00€100mg505.00€200mg705.00€1mL*10mM (DMSO)86.00€BMS-1001
CAS:BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction(IC50 : 2.25 nM, in a homogenous time-resolved fluorescence binding assay).Formula:C35H34N2O7Purity:98.43%Color and Shape:SolidMolecular weight:594.7Ref: TM-T8470
1mg58.00€5mg124.00€10mg177.00€25mg299.00€50mg424.00€100mg587.00€200mg792.00€1mL*10mM (DMSO)172.00€Socazolimab
CAS:Socazolimab (ZKAB001) is a monoclonal antibody targeting PD-L1 with antitumor activity, used in studies of recurrent or metastatic cervical cancer.Purity:95%Color and Shape:LiquidMolecular weight:143.06 kDaEnvafolimab
CAS:Envafolimab (ASC 22) is a humanized antibody targeting PD-L1, with anticancer activity, blocking the PD-L1 and PD-1 interaction.Purity:95%Color and Shape:LiquidMolecular weight:80 kDaBMS-1166-n-piperidine-co-n-piperazine dihydrochloride
CAS:BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride is a resorcinol di-Ph ether scaffold-based programmed cell death-1 (PD-1)/programmed cell death ligand 1 (Formula:C41H45Cl3N4O5Purity:98.94%Color and Shape:SoildMolecular weight:780.18ARB-272572
CAS:ARB-272572 is a PD-L1 signaling inhibitor that produces immunostimulatory activity in human primary cells.Formula:C32H36N6O4Purity:97.36% - 98.07%Color and Shape:SolidMolecular weight:568.67Ref: TM-T39914
1mg123.00€5mg295.00€10mg425.00€25mg712.00€50mg1,035.00€100mg1,485.00€200mg1,998.00€1mL*10mM (DMSO)353.00€Ivonescimab
CAS:Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody with cancer immunotherapy and anti-angiogenic effects, NSCLC).Purity:95% - >95.0% (SDS-PAGE); 98.99% (SEC-HPLC)Color and Shape:LiquidMolecular weight:201.12 kDaToripalimab
CAS:Toripalimab is a humanized anti-PD-1 monoclonal antibody used as an immune checkpoint inhibitor in research for advanced malignancies like nasopharyngeal carcinoma.Purity:95% - 95.2% (SDS-PAGE); 96.8% (SEC-HPLC)Color and Shape:LiquidSugemalimab
CAS:Sugemalimab, Anti-PD-L1 mAb, induces ADCC, for EGFR/ALK-negative metastatic NSCLC, solid tumors, and lymphoma research.Purity:95% - 95%Color and Shape:LiquidGilvetmab
CAS:Gilvetmab is a caninized anti-PD-1 antibody approved for veterinary use, researched for stage I-III mast cell tumors and stage II-III melanoma in dogs.Purity:95% - 97.9% (SDS-PAGE); 97.4% (SEC-HPLC)Color and Shape:LiquidMolecular weight:147.95 kDaReozalimab
CAS:Reozalimab (LY3434172) is a bispecific monoclonal antibody targeting PD-1/PD-L1, antitumour and enhances T-cell activation in vitro.Purity:95% - 98.1% (SDS-PAGE); 96.2% (SEC-HPLC)Color and Shape:LiquidMolecular weight:144.16 kDaLesabelimab
CAS:Lesabelimab (LDP) is an anti-CD274 monoclonal antibody of the immunoglobulin G1-kappa subclass.Color and Shape:LiquidRosnilimab
CAS:Rosnilimab is a PD-1 agonist that inhibits T cell proliferation and depletes T cells, enabling research into inflammatory diseases.Purity:95% - 98.9% (SDS-PAGE); 98.7% (SEC-HPLC)Color and Shape:LiquidMolecular weight:146.57 kDaAcasunlimab
CAS:Acasunlimab (GEN1046) is a bsAb that targets PD-L1 and 4-1BB, boosting T/NK cells and blocking PD-1/PD-L1 in cancer research.Color and Shape:LiquidTuvonralimab
CAS:Tuvonralimab, a combo of anti-PD-1/IgG4 and anti-CTLA-4/IgG1 antibodies, blocks dual immune checkpoints.Purity:95% - 95%Color and Shape:Liquid
